RT Journal Article
SR Electronic
T1 Effects of THAM Nasal Alkalinization on Airway Microbial Communities: A Pilot Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.14.21251657
DO 10.1101/2021.02.14.21251657
A1 Holliday, Zachary M.
A1 Launspach, Janice L.
A1 Durairaj, Lakshmi
A1 Singh, Pradeep K.
A1 Zabner, Joseph
A1 Stoltz, David A.
YR 2021
UL http://medrxiv.org/content/early/2021/02/16/2021.02.14.21251657.abstract
AB Objectives In cystic fibrosis (CF), loss of CFTR-mediated bicarbonate secretion reduces the airway surface liquid (ASL) pH causing airway host defense defects. Aerosolized sodium bicarbonate can reverse these defects, but its effects are short-lived. Aerosolized tromethamine (THAM) also raises the ASL pH but its effects are much longer lasting. In this pilot study, we tested the hypothesis that nasally administered THAM would alter the nasal bacterial composition in adults with and without CF.Methods Subjects (n=32 total) received intranasally administered normal saline or THAM followed by a wash out period prior to receiving the other treatment. Nasal bacterial cultures were obtained prior to and after each treatment period.Results At baseline, nasal swab bacterial counts were similar between non-CF and CF subjects, but CF subjects had reduced microbial diversity. Both nasal saline and THAM were well-tolerated. In non-CF subjects, nasal airway alkalinization decreased both the total bacterial density and the gram-positive bacterial species recovered. In both non-CF and CF subjects, THAM decreased the amount of C. accolens detected, but increased the amount of C. pseudodiphtheriticum recovered on nasal swabs. A reduction in S. aureus nasal colonization was also found in subjects who grew C. pseudodiphtheriticum.Conclusions This study shows that aerosolized THAM is safe and well-tolerated and that nasal airway alkalinization alters the composition of mucosal bacterial communities.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03078088Funding StatementThis research was supported, in part, by the NIH (HL136813, HL091842, and HL007638), and the Cystic Fibrosis Foundation (Iowa Cystic Fibrosis Foundation Research Development Program). This study was also supported by the National Center For Advancing Translational Sciences of the NIH under award number UL1TR002537.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Iowa IRB as well as the FDA approved the studies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from Drs. Zabner and Stoltz.